BlueBrainBoost
freedom-pharmacy
Purchases through the above links give commission which helps fund this website
Recent literature: GLP-1 receptor agonist
Date Journal Article title
2019 Aug Int J Mol Sci The Effects of Dual GLP-1GIP Receptor Agonism on Glucagon Secretion-A Review.
2019 Aug Diabetes Ther Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes.
2019 Aug Diabetes Technol Ther Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide-1 Receptor Agonist.
2019 Aug Rev Med Suisse [Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes].
2019 Aug PLoS Biol Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells.
2019 Aug Life Sci Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity.
2019 Aug Lancet Diabetes Endocrinol Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
2019 Aug Eur J Pharmacol Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways.
2019 Aug CNS Neurosci Ther D-Ser2-oxyntomodulin ameliorated Aβ31-35-induced circadian rhythm disorder in mice.
2019 Trends Endocrinol Metab Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials.
2019 Aug Br J Clin Pharmacol Polyethylene glycol loxenatide (PEX168) in jects with renal impairment: A pharmacokinetic study.
2019 J Diabetes Res Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.
2019 Front Pharmacol Liraglutide Increases VEGF Expression iviai CNPY2-PERK Pathway Induced by HypoxiaReoxygenation Injury.
2019 Aug Diabetes Metab Type 2 diabetes: Why should diabetologists and cardiologists work more closely together?
2019 Aug Diabetes Obes Metab Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of Body Mass Index.
2019 Aug Cell Rep The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release.
2019 Sep Org Biomol Chem Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects.
2019 Aug Clin Exp Pharmacol Physiol Chronic treatment of JTP-109192, a novel G-protein coupled receptor 119 agonist, improves metabolic abnormalities in Zucker Fatty rats.
2019 Aug Diabetes Obes Metab Diabetes drugs and stroke risk: intensive vs. conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials.
2019 Aug Pharm Dev Technol Preparation and evaluation of lactic acid acylated exenatide and its long-acting preparation.
2019 Jul Diabetes Obes Metab Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
2019 Adv Ther Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin GlargineLixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.
2019 Jul Diabetes Ther Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program.
2019 Jul Sci Rep High-throughput identification of peptide agonists against GPCRs by co-culture of mammalian reporter cells and peptide-secreting yeast cells using droplet microfluidics.
2019 Jul Ann Intern Med Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
2019 Jul Curr Cardiol Rep Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
2019 Lancet Child Adolesc Health FDA approval of GLP-1 receptor agonist (liraglutide) for use in children.
2019 Jul Br J Clin Pharmacol Liraglutide treatment reduced interleukin 6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy.
2019 Jul Int J Mol Sci Glucagon-Like Peptide-1 Receptor Agonist Attenuates Autophagy to Ameliorate Pulmonary Arterial Hypertension through Drp1NOX- and Atg-5Atg-7Beclin-1LC3β Pathways.
2019 Jul Diabet Med Addition of low-dose liraglutide to insulin therapy is useful for glycaemic control during the peri-operative period: effect of glucagon-like peptide-1 receptor agonist therapy on glycaemic control in patients undergoing cardiac surgery (GLOLIA study).
2019 Jul Curr Pharm Des Protein Tyrosine Phosphatase 1B inhibitors: a novel therapeutic strategy for the management of type 2 diabetes mellitus.
2019 Jul Int J Mol Sci A Dual GLP-1GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
2019 Jul Atherosclerosis Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
2019 Diabetes Care Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
2019 Aug - Aten Primaria [Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes].
2019 Jul J Diabetes Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
2019 Jul Microcirculation Assessment of real-time and quantitative changes in renal hemodynamics in healthy overweight males: contrast-enhanced ultrasonography versus para-aminohippuric acid clearance.
2019 Jul Neurogastroenterol Motil GHSR-1 agonist sensitizes rat colonic intrinsic and extrinsic neurons to exendin-4: A role in the manifestation of postprandial gastrointestinal symptoms in irritable bowel syndrome?
2019 Jun Pharmacoeconomic Review R...
2019 Medicine (Baltimore) Circulating alarin concentrations are high in patients with type 2 diabetes and increased by glucagon-like peptide-1 receptor agonist treatment: An Consort-compliant study.
2019 Aug Arch Biochem Biophys Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation.
2019 Jul Basic Clin Pharmacol Toxicol Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long-term impairment of the GIP system.
2019 Jul Diabetes Obes Metab Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.
2019 Sep J Biotechnol In-vivo half-life and hypoglycemic bioactivity of a fusion protein of exenatide and elastin-based polypeptide from recombinant Saccharomyces cerevisiae.
2019 J Pharmacol Exp Ther Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators.
2019 Jul Curr Pharm Des Liraglutide for the treatment of obesity: Analyzing published reviews.
2019 Jul Handb Exp Pharmacol Chenodeoxycholic Acid: An Update on Its Therapeutic Applications.
2019 Jul Diabetes Obes Metab Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study.
2019 Jun Int J Mol Sci Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence.
2019 Aug Biochem Biophys Res Commun Exendin-4 enhances proliferation of senescent osteoblasts through activation of the IGF-1IGF-1R signaling pathway.
2019 Jun Endocr Pract EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.
2019 Diabetes Res Clin Pract The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials.
2019 Aug Am J Physiol Endocrinol M... Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes.
2019 Int J Endocrinol Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1AMPK Signaling Pathway.
2019 Jun World J Diabetes Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications.
2019 Reprod Biomed Online GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
2019 Diabetes Ther Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).
2019 Jun Diabetes Obes Metab Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.
2019 Jun Ann Pharmacother The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin.
2019 Jun Obes Surg Duodenal-Jejunal Bypass Maintains Gut Permeability by Suppressing Gut Inflammation.
2019 Jun Cells Liraglutide Inhibits Endothelial-to-Mesenchymal Transition and Attenuates Neointima Formation after Endovascular Injury in Streptozotocin-Induced Diabetic Mice.
2019 Lancet Diabetes Endocrinol Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
2019 Lancet Diabetes Endocrinol Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
2019 Jul Lancet Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
2019 Jul Lancet Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
2019 Diabetes Care PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.
2019 Jul Lancet Oral semaglutide versus cutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
2019 Jul Lancet Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
2019 Jun N Engl J Med Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
2019 J Inflamm (Lond) The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKACREB pathway in a rat model of knee osteoarthritis.
2019 J Pharmacol Exp Ther SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.
2019 Aug Life Sci Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: Implications for lowering tissue damage.
2019 Jun Eur J Endocrinol Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.
2019 Apr Can J Diabetes Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials.
2019 Artif Cells Nanomed Biote... GLP-1 receptor agonist lixisenatide protects against high free fatty acids-induced oxidative stress and inflammatory response.